Sarepta Therapeutics (NASDAQ:SRPT) leads in genetic therapies, contributing to ongoing discussions surrounding the nasdaq ...

Dyne Therapeutics plans to submit its next-gen Duchenne muscular dystrophy drug to the FDA after a successful trial.

Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy, challenger from Massachusetts biotech Dyne ...

Wondering if Sarepta Therapeutics is a beaten down biotech bargain or a value trap? This article will walk through the numbers in plain English so you can decide with confidence. Despite a brutal long ...

The Food and Drug Administration said Friday it will add a new warning and other limitations to a gene therapy for Duchenne’s muscular dystrophy that's been linked to two patient deaths.The infused ...

Sarepta Therapeutics ( ($SRPT) ) has issued an announcement. On December 10, 2025, Sarepta Therapeutics entered into exchange agreements to ...